WallStSmart

Kestra Medical Technologies, Ltd. Common Stock (KMTS)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 67479% more annual revenue ($56.58B vs $83.72M). NVS leads profitability with a 23.9% profit margin vs -173.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

KMTS

Avoid

31

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -1.20

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KMTS.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KMTS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.7%10/10

Revenue surging 62.7% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

KMTS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.14B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-92.6%2/10

ROE of -92.6% — below average capital efficiency

Free Cash FlowQuality
$-28.16M2/10

Negative free cash flow — burning cash

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : KMTS

The strongest argument for KMTS centers on Revenue Growth, Debt/Equity. Revenue growth of 62.7% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : KMTS

The primary concerns for KMTS are EPS Growth, Market Cap, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

KMTS profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.

KMTS is growing revenue faster at 62.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 31/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kestra Medical Technologies, Ltd. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?